Phibro Animal Health (NASDAQ:PAHC) Cut to “Buy” at StockNews.com

StockNews.com lowered shares of Phibro Animal Health (NASDAQ:PAHC) from a strong-buy rating to a buy rating in a research report sent to investors on Sunday.

PAHC has been the topic of several other research reports. Morgan Stanley upped their target price on Phibro Animal Health from $20.00 to $25.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 17th. Barclays lifted their target price on Phibro Animal Health from $13.00 to $20.00 and gave the stock an “underweight” rating in a report on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $20.50.

Phibro Animal Health Trading Up 0.0 %

Shares of Phibro Animal Health stock opened at $20.28 on Friday. Phibro Animal Health has a 1 year low of $10.03 and a 1 year high of $25.98. The company has a market capitalization of $821.40 million, a price-to-earnings ratio of 47.16, a P/E/G ratio of 0.58 and a beta of 0.53. The business has a fifty day simple moving average of $22.66 and a two-hundred day simple moving average of $21.18. The company has a debt-to-equity ratio of 1.81, a current ratio of 3.23 and a quick ratio of 1.69.

Phibro Animal Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, December 18th. Shareholders of record on Wednesday, November 27th were given a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a yield of 2.37%. The ex-dividend date was Wednesday, November 27th. Phibro Animal Health’s dividend payout ratio is presently 111.63%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC grew its holdings in shares of Phibro Animal Health by 5.7% during the 3rd quarter. Geode Capital Management LLC now owns 507,469 shares of the company’s stock valued at $11,430,000 after purchasing an additional 27,201 shares during the last quarter. Barclays PLC lifted its stake in shares of Phibro Animal Health by 25.7% in the 3rd quarter. Barclays PLC now owns 143,337 shares of the company’s stock valued at $3,228,000 after acquiring an additional 29,271 shares during the last quarter. Zacks Investment Management acquired a new stake in shares of Phibro Animal Health during the 3rd quarter valued at $274,000. Virtus Investment Advisers Inc. grew its position in Phibro Animal Health by 65.1% during the 3rd quarter. Virtus Investment Advisers Inc. now owns 24,344 shares of the company’s stock worth $548,000 after acquiring an additional 9,600 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. increased its holdings in Phibro Animal Health by 116.6% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 192,255 shares of the company’s stock worth $4,330,000 after purchasing an additional 103,491 shares in the last quarter. Institutional investors own 99.34% of the company’s stock.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.